Outlook Therapeutics Inc (OTLK)

[goforthebet]

Outlook Therapeutics to Present Pivotal Data from NORSE TWO Trial at the 9th International Congress on OCT and OCT Angiography in Rome (ICOOR)/ FLORetina Symposia

Francesco Bandello, MD, FEBO, will present Phase 3 pivotal safety and efficacy data from the NORSE TWO registration trial
December 15, 2021 08:05 ET | Source: Outlook Therapeutics, Inc.
...
ISELIN, N.J., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Francesco Bandello, MD, FEBO, Professor and Chairman of the Department of Ophthalmology, University Vita-Salute, Ospedale San Raffaele, Milan, will present pivotal safety and efficacy data from Outlook Therapeutics’ Phase 3 NORSE TWO registration trial for ONS-5010 / LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for use in wet age-related macular degeneration (wet AMD). The presentation will take place at the 9th International Congress on OCT and OCT Angiography in Rome (ICOOR)/ FLORetina Symposia, on Saturday, December 18, 2021.

“The results observed for ONS-5010 in the NORSE TWO trial are potentially of great significance for retinal specialists and their patients suffering from wet AMD,” said Dr. Bandello. “I look forward to having an additional approved treatment option for patients that is on-label and specifically formulated and packaged to meet the stringent demands for ophthalmic use.”

Details for Dr. Bandello’s presentation are as follows:

Clinical and Efficacy Outcomes of the NORSE TWO Pivotal Study for ONS-5010, an Ophthalmic Formulation of Bevacizumab
Presenter: Francesco Bandello, MD, FEBO
Session: ICOOR 2021 Hall, Visions of Future by Industry and Engineers, Part 2
Date and time: Saturday, December 18, 2021, 5:48 AM – 5:54 AM Eastern Time (11:48 AM– 11:54 AM Central European Time)

For more information and to register for this event, please visit ICOOR 2021.

https://www.globenewswire.com/news-release/2021/12/15/2352619/0/en/Outlook-Therapeutics-to-Present-Pivotal-Data-from-NORSE-TWO-Trial-at-the-9th-International-Congress-on-OCT-and-OCT-Angiography-in-Rome-ICOOR-FLORetina-Symposia.html